Perioperative Plasma Levels of Glycocalyx Markers in Colon Surgery.

July 27, 2022 updated by: Nuria García del Olmo, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Study of Perioperative Plasma Levels of Endothelial Glycocalyx Markers in Patients Undergoing Colon Surgery.

The glycocalyx is a layer of macromolecules that covers the luminal surface of the endothelium, playing an important role in vascular homeostasis. Several studies have shown that in conditions of sepsis there is a degradation of the glycocalyx mediated by inflammatory mechanisms, releasing its components into the bloodstream. These glycocalyx fragments can be measured in blood plasma, showing a correlation between these markers and organ dysfunction, severity and mortality in sepsis situations. However, despite the great interest in glycocalyx biomarkers, their values in patients undergoing colorectal surgery are not well known. Therefore, verifying whether plasma levels of glycocalyx damage markers increase in the perioperative period of colorectal surgery is of great interest at the pathophysiological and clinical level, since the correlation of these markers with postoperative clinical evolution is unknown. In this study we want to determine the plasma levels of Heparan-sulphate and Syndecan-1, two of the most important constituents of the glycocalyx, and perform several measurements to form a "time course" of the plasma levels of these markers, in order to compare the different subgroups of patients undergoing colorectal surgery based on their clinical and surgical characteristics.

Study Overview

Status

Recruiting

Conditions

Detailed Description

BACKGROUND: The endothelial glycocalyx (EG) is a complex layer of macromolecules that lines the luminal surface of the vascular endothelium. This concept was proposed more than 70 years ago and its composition is well studied as detailed in two reviews (1, 2). However, its role in the mechanisms of endothelial protection and injury, and its subsequent clinical implications, have recently become evident. The EG consists of a variety of molecules, including glycoproteins and proteoglycans, that provide the basis for plasma-endothelial cell interaction. The structure of EG, although well characterized in vitro, is poorly defined in vivo because its composition changes dynamically by self-assembly and shear-dependent enzymatic degradation or detachment of its elements. Its major components are hyaluronic acid, proteoglycans (PG) such as syndecan-1, glycoproteins, plasma proteins and glycosaminoglycans (GAG), whose main component is Heparan Sulfate. The EG as a whole forms an endothelial surface layer that acts as a barrier to circulating cells and large molecules. Considerable prognostic-therapeutic promise lies in the emergence of the EG as a key mediator of endothelial dysfunction in pathogenic states, particularly with respect to vascular permeability and edema formation. Several studies have demonstrated the role of EG in plasma/interstitial fluid balance (3,4,5), mechano-transduction that couples intravascular pressure, and endothelial cell responses, i.e., biochemical signals, (6) to the inflammatory response cascade (7,8,9). EG damage affects a number of important endothelial cell functions leading to impaired mechano-transduction with changes in fluid passage (6,10), activation of coagulation pathways (11), leukocyte adhesion (7,11 ) and platelets (12) to the surface of endothelial cells, and leakage of fluid and plasma proteins into the interstitium (13,14), resulting in tissue edema (15). The specific pathophysiological triggers that lead to EG damage are still actively investigated and remain poorly understood. Nevertheless, EG protection appears to be a promising target in many clinical scenarios, especially since its degradation is closely associated with the pathophysiology of inflammation, capillary leak, and edema formation in various injuries and disease states; including ischemia/reperfusion, hypoxia, inflammation, trauma, hypervolemia, atherosclerosis, diabetes, and hypertension (16). In patients undergoing major abdominal surgery (including digestive, urological, gynecological or other surgery) there is very little information on the potential endothelial damage secondary to surgery (19). There are some reviews that have studied the damage of the EG in septic patients of medical and surgical origin (17, 18). However, in relation to digestive abdominal surgery, and specifically in colorectal surgery, only one study has been carried out, with only 18 patients undergoing colectomy (without mentioning the pathologies) and they are included with other patients of major abdominal surgery of the pancreas, liver, gynecology and urology (19).

EXPECTED RESULTS: In this study, it is expected that in the patients who underwent elective surgery, the markers of glycocalyx damage will increase their values in the postoperative laboratory tests compared to the values of the baseline (control) laboratory tests. It is equally expected that in patients undergoing urgent surgery, generally in clinical states of occlusion, perforation or sepsis, with activation of the inflammatory response, dehydration with decreased oncotic pressure and generation of tissue edema and third space, the markers of damage of glycocalyx are already elevated in the baseline analysis, with a maintenance or greater elevation of its values in the postoperative period. Likewise, a correlation would be expected between glycocalyx damage markers and other markers involved in the inflammatory response, such as leukocytes, C-reactive protein, procalcitonin, and lactate; as well as with associated patient comorbidities that lead to endothelial degeneration, such as high blood pressure, obesity, diabetes, atherosclerosis, etc. If the results of this study were as expected, glycocalyx damage markers (Heparan sulfate and Syndecan-1) could be used together with other inflammatory markers (C-reactive protein, procalcitonin, etc.) and be very useful in postoperative follow-up. of surgical patients, being able to anticipate possible postoperative complications. However, if elevations in glycocalyx markers were not observed in the perioperative period, it could be due to a lack of the number of Time-course determinations; that is to say, that an elevation of markers did occur, but we would not have detected it in the measurement times; or a larger study population might also be needed. In either case, the study could be completed in subsequent research projects.

OBJECTIVES:

Primary Objectives: To estimate the plasma levels of the 2 most representative markers of damage to the endothelial glycocalyx (Heparan-sulphate and Syndecan-1) in patients undergoing colorectal surgery during the perioperative period ("time-course").

Secondary Objectives:

  • To analyze a possible correlation of the Syndecan-1 and Heparan-sulphate levels with other analytical parameters (C-reactive protein, procalcitonin, lactate, blood count, coagulation and basic biochemistry).
  • To analyze the possible relationof glycocalyx damage markers with different parameters depending on the patient (age, sex and associated comorbidities) and the surgical intervention (surgical time, approach route, type of surgery…).
  • To analyze the possible relation of endothelial glycocalyx damage markers with other clinical parameters that may indicate a possible post-operative complication.

DESIGN METHODOLOGY: It is a clinical, prospective, observational, and longitudinal study of single-centre groups (Hospital Lluís Alcanyís, Xàtiva). Always after the approval of the Research Ethics Committee of said Hospital.

STUDY POPULATION: The study population (value of n ) has been calculated on a population of 100 patients who will undergo surgery approximately a year. With a confidence level of 95% and a margin of error of 5%, a sample size of 80 patients has been calculated. Said 80 patients will be older than age, men and women, undergoing elective or emergency colorectal surgery (right hemicolectomy, extended right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection of the rectum or abdominoperineal amputation).

SELECTION OF PATIENTS AND INFORMED CONSENT: Selection of patients and the drafting of the informed consent documents will be carried out in a reasoned manner as established in article 32 of the Helsinki Declaration and in article 58.2 of the Biomedical Research Law. It must be considered taking into account the Declaration of Helsinki of the World Medical Association in its latest revision. And according to its latest version of the Declaration of Helsinki of Fortaleza (Brazil) October 2013. Patients will be included in the study upon preoperative hospital admission, after verifying compliance with the inclusion criteria. To participate, the signature of the informed consent will be required.

Study Type

Observational

Enrollment (Anticipated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study population (value of n) has been calculated on a population of 100 patients who will undergo surgery approximately one year. With a confidence level of 95% and a margin of error of 5%, a sample size of 80 patients has been calculated. These 80 patients will be older than 18 years old, men and women, undergoing elective or emergency colorectal surgery (right hemicolectomy, extended right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection of the rectum or abdominoperineal amputation)

Description

Inclusion Criteria:

  • Signing of the informed consent document.
  • Age equal to or greater than 18 years.
  • American Society of Anesthesiologists (ASA) surgical risk ≤ III.
  • Undergoing colorectal surgery

Exclusion Criteria:

  • Age < 18 years old
  • Pregnant women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
colorectal surgery patients
In patients undergoing colorectal surgery, blood samples will be collected at 5 times: preoperatively, and at 2, 6, 24 and 48 hours after finishing surgery, respectively.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To analyze plasma levels changes of heparan-sulphate and syndecan-1 in perioperative period of colorectal surgery
Time Frame: Blood samples will be collected in 5 times: preoperatively, at 2 hours after surgery, 6 hours after surgery, 24 hours after surgery and 48 hours after surgery.
To analyze plasma levels changes of glycocalyx damage markers (Heparan-sulphate and Syndecan-1) at 5 times: preoperatively, 2 hours after surgery, 6 hours after surgery, 24 hours after surgery, and 48 hours after surgery, to perform a "time cours" of the plasma levels of this markers. This determinations will be made by ELISA technique.
Blood samples will be collected in 5 times: preoperatively, at 2 hours after surgery, 6 hours after surgery, 24 hours after surgery and 48 hours after surgery.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
C-reactive Protein, procalcitonin, lactate, complete blood count, coagulation and basic biochemistry
Time Frame: Blood samples will be collected in 5 times: preoperatively, at 2 hours after surgery, 6 hours after surgery, 24 hours after surgery and 48 hours after surgery.
To analyze the possible correlation of the levels of Heparan-sulphate and Syndecan-1, with other analytical parameters (C-reactive protein, procalcitonin, lactate, complete blood count, coagulation and basic biochemistry).
Blood samples will be collected in 5 times: preoperatively, at 2 hours after surgery, 6 hours after surgery, 24 hours after surgery and 48 hours after surgery.
To analyze the possible relationship of glycocalyx damage markers with different parameters depending on the patient and the surgical intervention
Time Frame: Blood samples will be collected in 5 times: preoperatively, at 2 hours after surgery, 6 hours after surgery, 24 hours after surgery and 48 hours after surgery.
To analyze the possible relationship of glycocalyx damage markers with different parameters depending on the patient (age, sex and associated comorbidities) and the surgical intervention (surgical time, approach route, type of surgery...).
Blood samples will be collected in 5 times: preoperatively, at 2 hours after surgery, 6 hours after surgery, 24 hours after surgery and 48 hours after surgery.
To study other clinical parameters that may indicate a possible postoperative complication and its relationship with markers of endothelial glycocalyx damage.
Time Frame: Blood samples will be collected in 5 times: preoperatively, at 2 hours after surgery, 6 hours after surgery, 24 hours after surgery and 48 hours after surgery.
study other clinical parameters that may indicate a possible postoperative complication (such as paralytic ileus, anastomotic leak, abdominal collections...) and its relationship with markers of endothelial glycocalyx damage.
Blood samples will be collected in 5 times: preoperatively, at 2 hours after surgery, 6 hours after surgery, 24 hours after surgery and 48 hours after surgery.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Investigators

  • Principal Investigator: Nuria García del Olmo, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2022

Primary Completion (Anticipated)

March 1, 2023

Study Completion (Anticipated)

March 1, 2023

Study Registration Dates

First Submitted

May 30, 2022

First Submitted That Met QC Criteria

June 10, 2022

First Posted (Actual)

June 15, 2022

Study Record Updates

Last Update Posted (Actual)

August 1, 2022

Last Update Submitted That Met QC Criteria

July 27, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • FISABIO

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endothelial Dysfunction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe